MaxCyte to acquire cell therapy supplier for $151.8M
MaxCyte has entered an agreement to acquire Akron Bio for $151.8 million, a deal expected to nearly double its revenue base and expand its cell therapy manufacturing business. The transaction, announced Nov. 10, is expected to close before the end of 2026, subject to customary closing conditions. Akron supplies materials used in cell therapy manufacturing, […] The post MaxCyte to acquire cell therapy supplier for $151.8M appeared first on Becker's Hospital Review | Healthcare News &am...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.